-
1 Comment
Burning Rock Biotech Limited is currently in a long term downtrend where the price is trading 7.5% below its 200 day moving average.
From a valuation standpoint, the stock is 97.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 29.7.
Burning Rock Biotech Limited's total revenue rose by 48.5% to $132M since the same quarter in the previous year.
Its net income has dropped by 64.6% to $-156M since the same quarter in the previous year.
Finally, its free cash flow fell by 73.4% to $-166M since the same quarter in the previous year.
Based on the above factors, Burning Rock Biotech Limited gets an overall score of 2/5.
| Exchange | NASDAQ |
|---|---|
| CurrencyCode | USD |
| ISIN | US12233L1070 |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Market Cap | 30M |
|---|---|
| PE Ratio | None |
| Target Price | 4.03 |
| Beta | 0.67 |
| Dividend Yield | None |
Burning Rock Biotech Limited primarily develops and sells cancer therapy selection tests in the People's Republic of China. It operates through three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; and OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC. The company also provides ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and brPROPHET, a pre-operative ctDNA detection and post-operative MRD calling for relapsed patients, as well as Magnis BR-customized version of its principal products. In addition, it offers OncoMaster, an automatic NGS data analysis and report interpretation machine for in-hospital model. Burning Rock Biotech Limited has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, Boehringer Ingelheim, and Merck KGaA. The company was founded in 2014 and is headquartered in Guangzhou, the People's Republic of China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for BNR using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
